Escolar DM, Scacheri CG: Pharmacologic and genetic therapy for childhood muscular dystrophies. Current Neurology and Neuroscience Reports. 2001, 1: 168-174.
Article
CAS
PubMed
Google Scholar
Griggs RC, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP, Cwik VA, Pandya S, Robison J, et al: Duchenne dystrophy: Randomized, controlled trial of prednisone (18 months) and azathioprine (12 months). Neurology. 1993, 43: 520-527.
Article
CAS
PubMed
Google Scholar
Fenichel GM, Mendell JR, Moxley RT, Brooke MH, Griggs RC, Miller JP, Pestronk A, Robison J, King W, Signore L, et al: A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. Arch Neurol. 1991, 48: 575-579.
Article
CAS
PubMed
Google Scholar
Griggs RC, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP, and the Clinical Investigation of Duchenne Dystrophy: Prednisone in Duchenne dystrophy a randomized controlled trial defining the time course and dose response. Arch Neurol. 1991, 48: 383-388.
Article
CAS
PubMed
Google Scholar
Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, King W, Signore L, Pandya S, Florence J, et al: Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med. 1989, 320: 1592-1597.
Article
CAS
PubMed
Google Scholar
Biggar WD, Gingras M, Fehlings DL, Harris VA, Steele CA: Deflazacort treatment of Duchenne muscular dystrophy. J Pediatr. 2001, 138: 45-50. 10.1067/mpd.2001.109601.
Article
CAS
PubMed
Google Scholar
Deflazacort-FDA Summary Document. Marion Merrel Dow Inc. 1992
Emery AEH: The muscular dystrophies. Lancet. 2002, 359: 687-695. 10.1016/S0140-6736(02)07815-7.
Article
CAS
PubMed
Google Scholar
Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF, for the QUOROM Group: Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet. 1999, 354: 1896-1900. 10.1016/S0140-6736(99)04149-5.
Article
CAS
PubMed
Google Scholar
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds JM, Gavaghan DJ, McQuay HJ: Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials. 1996, 17: 1-12. 10.1016/0197-2456(95)00134-4.
Article
CAS
PubMed
Google Scholar
Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995, 273: 408-412. 10.1001/jama.273.5.408.
Article
CAS
PubMed
Google Scholar
Brooke MH: A randomized trial of deflazacort and prednisone in Duchenne muscular dystrophy: efficacy and toxicity [abstract]. Neurology. 1996, 46: A476-
Article
Google Scholar
Reitter B: DMD Meeting. Neuromuscul Disord. 1998, 8: 216-
Google Scholar
Cook DJ, Guyatt GH, Ryan G, Clifton J, Buckingham L, Willan A, McIIroy W, Oxman AD: Should unpublished data be included in meta-analyses? Current convictions and controversies. JAMA. 1993, 269: 2749-2753. 10.1001/jama.269.21.2749.
Article
CAS
PubMed
Google Scholar
Moher D, Jadad AR, Tugwell P: Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care. 1996, 12: 195-208.
Article
CAS
PubMed
Google Scholar
Clarke M, Oxman AD, editors: Cochrane Reviewers Handbook 4.1.4 (updated October 2002). In: the Cochrane Library, Oxford Update Software. Updated quarterly. 2002
Moher D, Pham B, Jones A, Cook DJ, Jadad AR, Moher M, Tugwell P, Klassen TP: Does quality of reports of randomized trials affect estimates of intervention efficacy reported in meta-analysis?. Lancet. 1998, 352: 609-613. 10.1016/S0140-6736(98)01085-X.
Article
CAS
PubMed
Google Scholar
Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research design. N Engl J Med. 2000, 342: 1887-92. 10.1056/NEJM200006223422507.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bonifati MD, Ruzza G, Bonometto P, Berardinelli A, Gorni K, Orcesi S, Lanzi G, Angelini C: A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy. Muscle Nerve. 2000, 23: 1344-1347. 10.1002/1097-4598(200009)23:9<1344::AID-MUS4>3.3.CO;2-6.
Article
CAS
PubMed
Google Scholar
Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C: Deflazacort in Duchenne dystropy: study of long-term effect. Muscle Nerve. 1994, 17: 386-391.
Article
CAS
PubMed
Google Scholar
Mesa LE, Dubrovsky AL, Corderi J, Marco P, Flores D: Steroids in Duchenne muscular dystrophy-deflazacort trial. Neuromuscul Disord. 1991, 1: 261-266. 10.1016/0960-8966(91)90099-E.
Article
CAS
PubMed
Google Scholar
Reitter B: Deflazacort vs. prednisone in Duchenne muscular dystrophy: the trends of an ongoing study. Brain and Dev. 1995, 17 (suppl): 39-43. 10.1016/0387-7604(95)00015-1.
Article
Google Scholar
Luz Aviles C, Gutierrez C, Novoa F, Gil E, Stuardo A: Tratamiento esteroidal en distrofia muscular de Duchenne [Corticosteroids in the treatment of Duchenne's Muscular dystrophy]. Revista Chilena de Pediatria. 1982, 53: 187-191.
CAS
PubMed
Google Scholar
Angelini C, Bonifati MD, Ruzza G, Ermani M: Steroids in the management of Duchenne (DMD) and Limb-girdle muscular dystrophy (LGMD2D) [abstract]. Muscle Nerve. 1998, S71-
Google Scholar
Angelini C, Pegoraro E, Cadaldini M: Daily versus alternate-day deflazacort (dfz) in Duchenne muscular dystrophy. Neurology. 1995, 45 (suppl 4): A182-
Google Scholar
Reitter B: Motor performance of DMD boys treated with prednisone or deflazacort: interim results of a double-blind study [abstract]. Dev Med Child Neurol. 1995, 37 (supp 72): 107-
Google Scholar
Winter K, Schara U, Mortier J, Liersch R, Mortier W: Duchenne muscular dystrophy with long term steroid therapy absence of cardiac side effects. Acta Myologica. 1999, 3: 159-162.
Google Scholar
Reitter B: Deflazacort im Vergleich zu Prednison bei Muskeldystrophie Duchenne (DMD): Zwischenbericht einer Multicenter-Studie [Deflazacort in comparison with Prednisone in Muscle dystrophy duchenne (DMD): Interim report of a multi-centre study.]. Monatsschrift fur Kinderheilkunde. 1995, 143: S208-
Google Scholar
Todorovic SM: High dose (2 mg/kg) alternate day prednisone therapy in the treatment of Duchenne muscular dystrophy [abstract]. Muscle Nerve. 1998, S72-
Google Scholar
Dubrovsky AL, De Vito E, Suarez A, Mesa LE, Pessolano F, Sobrino R, Andrada L, Roncroni A: Deflazacort treatment and respiratory function in Duchenne muscular dystrophy [abstract]. Neurology. 1999, 52 (suppl 2): A544-
Google Scholar
Dubowitz V chairman: 47th ENMC International Workshop: Treatment of Muscular Dystrophy: 1996 December 13–15; Naarden, The Netherlands. Neuromuscul Disord. 1997, 7: 261-267.
Google Scholar
Angelini C: Multicenter trials in Duchene muscular dystrophy: Natural history and experience with a calcium antagonist or branched chain amino acids. Muscle Nerve. 1985, 8: 474-477.
Google Scholar
Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley RT, Miller JP, Kaiser KK, Florence JM, Pandya S, Sigmore L, et al: Clinical investigation of Duchene muscular dystrophy. Interesting results in a trial of prednisone. Arch Neurol. 1987, 44: 812-817.
Article
CAS
PubMed
Google Scholar